



Health, Seniors and Long-Term Care
Insurance Division
300 Carlton Street
Winnipeg, Manitoba Canada R3B 3M9

Information for Pharmacists

Claims Submission Procedure – COVID-19 Oral Antiviral Drugs (Paxlovid) Effective May 20, 2022 Updated October 24, 2024

**Please include this Procedure in your Drug Programs Information
Network (DPIN) Manual under Section 4: Claims Submission.**

- This Claims Submission Procedure (CSP) applies to community pharmacy dispensation of oral antiviral drugs covered on the Manitoba Drug Benefits Formulary (MDBF) **prescribed for the purpose of COVID-19 treatment (i.e., Paxlovid)** to eligible Manitoba residents with active Manitoba Health coverage who do not have 100% coverage under another government funded program;
 - Not eligible for coverage: Clients with federal or other provincial drug coverage where no deductibles apply (including clients enrolled in Manitoba's Personal Care Home, Employment and Income Assistance [EIA], and Palliative Care Drug Access Program)
 - Eligible for coverage: Clients enrolled in the Manitoba Pharmacare program, and clients ELIGIBLE to enroll in Pharmacare because they do not have coverage under another federal or provincial government drug program.
- Effective October 24, 2024:
 - The coverage and associated processes established in the prior version of the CSP – COVID-19 Oral Antiviral Drugs are no longer in effect. **Claims for COVID-19 oral antiviral drugs dispensed according to these expired procedures on or after October 24, 2024 will not be reimbursed by the department.**
 - COVID-19 oral antiviral drugs (i.e., Paxlovid) have been listed under the Drugs Provided at No Cost section of the MDBF as Part 2 benefits. Please refer to the MDBF for eligibility criteria: <https://www.gov.mb.ca/health/mdbif/docs/manitoba-drug-benefits-formulary.pdf>.
- Pharmacies must submit claims for COVID-19 oral antiviral drugs to Drug Program Information Network (DPIN) under the new Public Health (PH) Carrier Code, 06.
- Pharmacies may charge a **maximum \$14 professional fee** for claims for COVID-19 oral antiviral drugs medications submitted through the PH carrier code.
- Manitoba will not reimburse pharmacies for more than one (1) professional fee per month for COVID-19 oral antiviral drugs submitted through the PH carrier code. "One (1) month" refers to a per 30-day period or 28-day cycle.
- Before submitting a COVID-19 oral antiviral drug claim to DPIN under the PH carrier code – carrier code 06 – the following must be undertaken;
 1. The client must be asked to self-declare whether they are eligible for coverage under a federal drug program, and if so, the claim must be processed under that federal program. Pharmacies must keep a record of the individual's response to this inquiry that corresponds with each COVID-19 oral antiviral drug dispensation.

2. If the client declares they do not have coverage under a federal drug program, the client must be asked to self-declare whether they are eligible for coverage under any of the following provincial drug programs (and if so, the claim must be processed under the associated carrier code; pharmacies must keep a record of the individual's response to this inquiry that corresponds with each COVID-19 oral antiviral drug dispensation):
 - Personal Care Home – carrier code 02
 - Employment and Income Assistance (EIA) – carrier code 03
 - Palliative Care – carrier code 04

If your questions are not answered by reviewing the Claims Submission Procedures and FAQs posted at:
<https://www.gov.mb.ca/health/pharmacare/healthprofessionals.html>

Please send an e-mail to PDPInfoAudit@gov.mb.ca.